دورية أكاديمية
أعرض في EDS

Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer.

التفاصيل البيبلوغرافية
العنوان: Robotic retroperitoneal lymph node dissection for primary and post-chemotherapy testis cancer.
المؤلفون: Nason GJ; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Suite 3-130, Toronto, ON, M5G 1X5, Canada., Kuhathaas K; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Suite 3-130, Toronto, ON, M5G 1X5, Canada., Anson-Cartwright L; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Suite 3-130, Toronto, ON, M5G 1X5, Canada., Jewett MAS; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Suite 3-130, Toronto, ON, M5G 1X5, Canada., O'Malley M; Division of Abdominal Imaging, Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, Canada., Sweet J; Department of Pathology and Lab Medicine, University Health Network, University of Toronto, Toronto, ON, Canada., Hansen A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Bedard P; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Chung P; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Hahn E; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Warde P; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada., Hamilton RJ; Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, 610 University Avenue, Suite 3-130, Toronto, ON, M5G 1X5, Canada. rob.hamilton@uhn.ca.
المصدر: Journal of robotic surgery [J Robot Surg] 2022 Apr; Vol. 16 (2), pp. 369-375. Date of Electronic Publication: 2021 May 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Country of Publication: England NLM ID: 101300401 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1863-2491 (Electronic) Linking ISSN: 18632483 NLM ISO Abbreviation: J Robot Surg Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Springer
مواضيع طبية MeSH: Neoplasms, Germ Cell and Embryonal*/drug therapy , Neoplasms, Germ Cell and Embryonal*/surgery , Robotic Surgical Procedures*/methods , Testicular Neoplasms*/drug therapy , Testicular Neoplasms*/pathology , Testicular Neoplasms*/surgery, Humans ; Lymph Node Excision/methods ; Male ; Retroperitoneal Space/surgery ; Retrospective Studies ; Treatment Outcome
مستخلص: The role of retroperitoneal lymph node dissection (RPLND) in testicular cancer is well established in both the primary and post-chemotherapy setting. The aim of this study was to report our 2 years oncological outcomes of robotic RPLND. A retrospective review was performed of all patients undergoing robotic RPLND by a single surgeon at Princess Margaret Cancer Centre. Demographic, perioperative, and oncologic data were analyzed using descriptive statistics. Between September 2014 and June 2020, 141 patients underwent an RPLND [33 (23.4%) were primary, 108 (76.6%) were post-chemotherapy]. 27 (19.1%) patients underwent a robotic bilateral template nerve-sparing RPLND. RPLND indication was primary (i.e. pre-chemotherapy) in 18 (66.7%), and post-chemotherapy in 9 (33.3%) patients. Stage at RPLND was 2A (n = 15, 55.6%), 2B (n = 9, 33.3%), 2C (n = 1, 3.7%) and 3 (n = 2, 7.4%). Median OR time (incision to closure) was 525 min and blood loss was 200 ml. Nerve sparing was performed in all but one case. Six (22.2%) adjuvant procedures were performed including two (7.4%) vascular repairs. Median length of stay was 2 days. Viable tumor was detected in 17 (63%) and teratoma in 9 (33.3%). Median follow-up was 31.3 months. No adjuvant chemotherapy was given. Three patients (11.1%) relapsed: 2 out-of-field and 1 with both in-field and out-of-field disease. Robotic RPLND can be performed safely. Long-term follow-up of series such as ours, enriched with patients with viable disease and/or teratoma, and not treated with adjuvant chemotherapy is required to ensure oncological outcomes are comparable to the open approach.
(© 2021. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.)
التعليقات: Comment in: J Urol. 2023 Jun;209(6):1232. (PMID: 36950940)
References: Albers P, Albrecht W, Algaba F et al (2015) Guidelines on testicular cancer: 2015 update. Eur Urol 68(6):1054–1068. (PMID: 10.1016/j.eururo.2015.07.044)
Stephenson A, Eggener SE, Bass EB et al (2019) Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol 202(2):272–281. (PMID: 10.1097/JU.0000000000000318)
Gilligan T, Lin DW, Aggarwal R et al (2019) Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(12):1529–1554. (PMID: 10.6004/jnccn.2019.0058)
Hamilton RJ, Nayan M, Anson-Cartwright L et al (2019) Treatment of relapse of clinical stage I nonseminomatous germ cell tumors on surveillance. J Clin Oncol 37(22):1919–1926. (PMID: 10.1200/JCO.18.01250)
Shayegan B, Carver BS, Stasi J et al (2007) Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU Int 99(5):993–997. (PMID: 10.1111/j.1464-410X.2007.06740.x)
Chovanec M, Abu Zaid M, Hanna N et al (2017) Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 28(11):2670–2679. (PMID: 10.1093/annonc/mdx360)
Kundu SD, Feldman DR, Carver BS et al (2015) Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. J Urol 193(2):513–518. (PMID: 10.1016/j.juro.2014.08.081)
Heidenreich A, Albers P, Hartmann M et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169(5):1710–1714. (PMID: 10.1097/01.ju.0000060960.18092.54)
Rukstalis DB, Chodak GW (1992) Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J Urol 148(6):1907–1909 (discussion 1909-10). (PMID: 10.1016/S0022-5347(17)37068-4)
Davol P, Sumfest J, Rukstalis D (2006) Robotic-assisted laparoscopic retroperitoneal lymph node dissection. Urology 67(1):199. (PMID: 10.1016/j.urology.2005.07.022)
Cheney SM, Andrews PE, Leibovich BC et al (2015) Robot-assisted retroperitoneal lymph node dissection: technique and initial case series of 18 patients. BJU Int 115(1):114–120. (PMID: 10.1111/bju.12804)
Pearce SM, Golan S, Gorin MA et al (2017) Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. Eur Urol 71(3):476–482. (PMID: 10.1016/j.eururo.2016.05.017)
Overs C, Beauval JB, Mourey L et al (2018) Robot-assisted post-chemotherapy retroperitoneal lymph node dissection in germ cell tumor: is the single-docking with lateral approach relevant? World J Urol 36(4):655–661. (PMID: 10.1007/s00345-018-2177-y)
Rocco NR, Stroup SP, Abdul-Muhsin HM et al (2020) Primary robotic RLPND for nonseminomatous germ cell testicular cancer: a two-center analysis of intermediate oncologic and safety outcomes. World J Urol 38(4):859–867. (PMID: 10.1007/s00345-019-02900-w)
Singh A, Chatterjee S, Bansal P et al (2017) Robot-assisted retroperitoneal lymph node dissection: feasibility and outcome in postchemotherapy residual mass in testicular cancer. Indian J Urol 33(4):304–309. (PMID: 10.4103/iju.IJU_8_17)
Stepanian S, Patel M, Porter J (2016) Robot-assisted laparoscopic retroperitoneal lymph node dissection for testicular cancer: evolution of the technique. Eur Urol 70(4):661–667. (PMID: 10.1016/j.eururo.2016.03.031)
Klaassen Z, Hamilton RJ (2019) The role of robotic retroperitoneal lymph node dissection for testis cancer. Urol Clin North Am 46(3):409–417. (PMID: 10.1016/j.ucl.2019.04.009)
Mittakanti HR, Porter JR (2020) Robot-assisted laparoscopic retroperitoneal lymph node dissection: a minimally invasive surgical approach for testicular cancer. Transl Androl Urol 9(Suppl 1):S66–S73. (PMID: 10.21037/tau.2019.12.36)
Beck SD, Foster RS, Bihrle R et al (2007) Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 110(6):1235–1240. (PMID: 10.1002/cncr.22898)
Masterson TA, Carver BS, Abel EJ et al (2012) Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. BJU Int 110(7):950–955. (PMID: 10.1111/j.1464-410X.2012.10947.x)
Calaway AC, Einhorn LH, Masterson TA et al (2019) Adverse surgical outcomes associated with robotic retroperitoneal lymph node dissection among patients with testicular cancer. Eur Urol 76(5):607–609. (PMID: 10.1016/j.eururo.2019.05.031)
Taylor J, Becher E, Wysock JS et al (2020) Primary robot-assisted retroperitoneal lymph node dissection for men with nonseminomatous germ cell tumor: experience from a multi-institutional cohort. Eur Urol Focus S2405–4569(20):30172–30173.
Williams SB, McDermott DW, Winston D et al (2010) Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data. BJU Int 105(7):918–921. (PMID: 10.1111/j.1464-410X.2009.08888.x)
Sheinfeld J, Feldman DR, DiNatale RG et al (2019) Altering the natural history of surgical relapse in testicular cancer: suboptimal surgery and pneumoperitoneum. Eur Urol 76(5):612–614. (PMID: 10.1016/j.eururo.2019.07.016)
Porter J, Eggener S, Castle E, Pierorazio P (2019) Recurrence after robotic retroperitoneal lymph node dissection raises more questions than answers. Eur Urol 76(5):610–611. (PMID: 10.1016/j.eururo.2019.08.013)
Nason GJ, Jewett MAS, Hamilton RJ (2019) Re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol 2019;76:607-9. Eur Urol 76(5):e139–e140. (PMID: 10.1016/j.eururo.2019.08.001)
فهرسة مساهمة: Keywords: Germ cell tumor; RPLND; Robotic; Testis cancer
تواريخ الأحداث: Date Created: 20210513 Date Completed: 20220330 Latest Revision: 20230510
رمز التحديث: 20240829
DOI: 10.1007/s11701-021-01252-1
PMID: 33982173
قاعدة البيانات: MEDLINE
الوصف
تدمد:1863-2491
DOI:10.1007/s11701-021-01252-1